It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Mary Jo Fidler, MD

Patient Feedback
  • Oncology, Medical
  • Hematology
  • Internal Medicine
Board Certification:
  • Medical Oncology
  • Hematology
Faculty Rank: Associate Professor
Medical or Graduate Education: Albert Einstein College of Medicine
Residency: McGaw Medical Center of Northwestern University - Internal Medicine
Fellowship: Rush University Medical Center - Hematology/Oncology
Clinical Expertise:
  • Head and neck tumors
  • Lung cancer
  • Mesothelioma
Research Interests:
  • Targeting the epidermal growth factor receptor in head and neck cancer
  • Anti-angiogenic therapy and radiation for locally advanced lung cancer
  • Protein and gene expression, locally advanced non-small cell lung cancer
  • Epidermal growth factor receptor pathway, non-small cell lung cancer
Languages Spoken:
  • Spanish
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.
    O'Mahony S, Nathan S, Mohajer R, Bonomi P, Batus M, Fidler MJ, Wells K, Kern N, Sims S, Amin D
    Am J Hosp Palliat Care
    2015 Feb 10
  2. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ
    Pract Radiat Oncol
    2014 Sep-Oct
  3. Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing.
    Dandekar V, Morgan T, Turian J, Fidler MJ, Showel J, Nielsen T, Coleman J, Diaz A, Sher DJ
    Oral Oncol.
    2014 May
  4. Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution.
    Sher DJ, Liptay MJ, Fidler MJ
    Int. J. Radiat. Oncol. Biol. Phys.
    2014 Jun 1
  5. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ, Koshy M, Liptay MJ, Fidler MJ
    2014 Apr 1
  6. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.
    Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR
  7. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
    Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P.
    Anticancer Res. 2012
    2012 May
  8. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.
    Fidler MJ, Shersher DD, Borgia JA, Bonomi P.
    Ther Adv Med Oncol. 2012
    2012 Mar
    4(2):51-60. doi: 10.1177/1758834011427576.
  9. Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P.
    Clin Lung Cancer. 2012
    2012 Dec 20. doi:pii: S1525-7304(12)00263-X. 10.1016/j.cllc.2012.10.009. [Epub ahead of print]
  10. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
    Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Nov 15
    81(4):985-91. doi: 10.1016/j.ijrobp.2010.06.059. Epub 2010 Oct 6.
  11. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P.
    J Thorac Oncol. 2011
    2011 Jun
    6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.
  12. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer.
    Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ.
    Lung Cancer. 2011
    2011 Feb
    71(2):186-90. doi: 10.1016/j.lungcan.2010.05.006. Epub 2010 Jun 8.
  13. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M, Fidler MJ, Bonomi PD.
    Expert Rev Anticancer Ther. 2010
    2010 Oct
    10(10):1589-99. doi: 10.1586/era.10.104. Review.
  14. Immunotherapy to overcome lung tumor cell-induced escape from immunosurveillance.
    Plate JM, Fidler MJ.
    Immunotherapy. 2010
    2010 Nov
    2(6):757-60. doi: 10.2217/imt.10.62. No abstract available.
  15. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J.
    Int J Cancer. 2010
    2010 Apr 1
    126(7):1630-9. doi: 10.1002/ijc.24896.
  16. Treatment of locally advanced non-small cell lung cancer.
    Fidler MJ, Kim AW, Zusag T, Bonomi P.
    Clin Adv Hematol Oncol. 2009
    2009 Jul
    7(7):455-64, 479-80. Review.
  17. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res. 2008
    2008 Apr 1
    14(7):2088-94. doi: 10.1158/1078-0432.CCR-07-4013.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.